Americans Are Top Targets of China-Linked Asian Scam Centers: Report
While China reported a 30 percent decrease in money lost to online scams in 2024, the United States' loss increased by 42 percent, the U.S.—China Economic and Security Review Commission (USCC) said on July 18.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
These Old Coins and Banknotes Are Selling For More Than Real Estate
Some old coins and banknotes are selling for more than the cost of a home. These collectibles are drawing six-figure bids from buyers, pushing them into the same conversation as traditional investments like real estate. The right item, authenticated and auctioned, can deliver an outsized return, all without the maintenance, taxes or paperwork that come with owning property. Check Out: Read Next: Kuang-Hsü Tael (1906) In June 2025, a rare Chinese silver coin called the Kuang-hsü Tael from the Peh Family Collection sold for $810,000 at a Heritage Auctions event, according to CoinWeek. It's a coin few people have ever held in person, but collectors were willing to pay more than the average home price in cities like Austin ($523,769), Denver ($555,304) and Salt Lake City ($571,623). More Collectibles: Long-Whiskered Dragon Dollars (1911) The Peh Family Collection also produced two highly sought-after 1911 'Long-Whiskered Dragon' silver dollars that set auction records. A 'Restrike Specimen Pattern Long-Whiskered Dragon Dollar Year 3' (1911) graded SP63 by NGC sold for $504,000, while a nearly identical piece, graded SP63+, went for $408,000 — both fetching more than the average home price in Tucson ($331,789) or Jacksonville ($290,108). Netherlands Bank 100 Gulden Note (1814-1838) At the same auction, a Dutch banknote fetched $114,000. It wasn't gold, and it wasn't flashy, but it was rare and in great condition. For perspective, that single piece of paper sold for more than the average home in Detroit ($78,601). Why Collectibles Are Beating Property A decent home in a mid-sized city might take 90 days or more to sell. The seller covers taxes, agent commissions, repairs and closing costs. And unless it's in a booming market, the return often creeps up slowly, if at all. Compare that to the collectibles market. A coin can be shipped to an auction house, authenticated and sold to a global bidder base in days. No yard signs or home inspections, and a rare item in pristine condition can get instant interest and a fast sale. And while real estate is often limited by location, collectibles aren't. A coin stored in a desk drawer in New Jersey can sell to a buyer in Tokyo or Dubai without ever changing hands physically. That kind of mobility and liquidity makes coins and notes increasingly attractive, especially when markets are uncertain. Editor's note: Average home prices were sourced from More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard The 10 Most Reliable SUVs of 2025 How Far $750K Plus Social Security Goes in Retirement in Every US Region This article originally appeared on These Old Coins and Banknotes Are Selling For More Than Real Estate Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
World's First Mass-Produced Semi-Solid-State Battery EV Is Coming, And You Can't Have It
World's First Mass-Produced Semi-Solid-State Battery EV Is Coming, And You Can't Have It originally appeared on Autoblog. China is ahead of the game For most auto enthusiasts, solid-state batteries are viewed as the final hurdle for electric vehicles. These types of batteries offer a longer range, faster charging, and improved performance in extreme temperatures. Affordability is a problem; solid-state battery tech isn't new, but the industry has yet to produce it at scale, making it incredibly expensive. So why is a mid-range EV in China getting solid-state battery tech? MG Motor, a state-backed Chinese automaker, will soon produce a hatchback (the MG4) with semi-solid-state battery technology, and it will be available to buyers for 80,000 yuan to 120,000 yuan - or roughly $11,000 to $17,000. The MG4 - how it has solid-state battery tech In a conventional lithium-ion EV battery, liquid electrolyte travels between a positive cathode and a negative anode (both electrodes) to supply power. It's this specific movement of liquid that matters for battery performance; if you use more components in your car, more of the liquid has to migrate through the battery, reducing its range. Similarly, using the AC or heat less helps you get the most from your EV's range. A solid-state battery has no liquid; instead, it uses a solid electrolyte for energy transfer between electrodes. This means far less time charging a battery, increased battery density (which translates to more power storage and, consequently, a more extended range), and possibly improved battery life. The MG4's 'semi-solid-state' battery is a step toward full solid-state battery technology in an EV. Instead of a liquid, the battery will use a gel electrolyte. Swapping liquid for gel is more easily and affordably produced than solid-state batteries. It also provides many of the stability, structural integrity, and thermal safety benefits of a proper solid-state battery. While there's no strict designation, a semi-solid-state battery is generally defined as one with less than 10 percent liquid electrolyte. The semi-solid-state battery used in the MG4 will be five percent liquid electrolyte. It has reportedly passed a 360-degree puncture test and achieved a 13.8 percent better range retention in cold weather compared to traditional lithium-ion phosphate battery technology. The battery density is 180 watt hours per kilogram, which leaves a lot to be desired. Tesla's 4680 lithium-ion cells, by comparison, offer at least 272 watt hours per kilogram. For an $11,000 EV, though, we're not going to complain too much. Final thoughts The worldwide auto industry may be overlooking semi-solid-state battery technology. While we're left wondering when solid-state batteries will hit EVs, MG Motor is at least trying something different. A 333-mile range isn't incredible, but it's more than adequate for most drivers. At this rate, the auto industry risks leaving itself in the same position mobile tech has been in for over a decade. Many have longed for solid-state battery technology to be made available for everything from smartphones to toothbrushes for years. The song has remained the same: it's too expensive to make solid-state batteries, and the infrastructure isn't available. Semi-solid-state batteries address many issues EV doubters have. It might be smarter to give people a step toward the end goal of solid-state rather than expecting them to hold off on electrifying their small garage fleet. Instead, everyone outside of China is left wanting. World's First Mass-Produced Semi-Solid-State Battery EV Is Coming, And You Can't Have It first appeared on Autoblog on Jul 25, 2025 This story was originally reported by Autoblog on Jul 25, 2025, where it first appeared.
